BioArctic
231,4 SEK -1,2%6 investorer følger denne virksomhed
BioArctic is a research company. The greatest business focus is found in the research and development of treatments and antibodies for diseases that affect the nervous system. Examples of various diseases mainly include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. The company was founded in 2003 and is headquartered in Stockholm, Sweden.
Omsætning
616 mio.
EBIT %
41,01 %
P/E
89
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
BIOA B
Daglig lav / høj pris
229 / 232,2
SEK
Markedsværdi
20,44 mia. SEK
Aktieomsætning
2,8 mio. SEK
Volumen
12 t
Seneste videoer
Finanskalender
Delårsrapport
29.08.2024
Delårsrapport
14.11.2024
Årsrapport
13.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Lars Lannfelt | 33,4 % | 49,2 % |
Pär Gellerfors | 21,6 % | 32,6 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
BioArctic: Leqembi[®] (lecanemab) launched in China
BioArctic: FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
BioArctic: Leqembi[®] approved for the treatment of Alzheimer's disease in South Korea
Bulletin from the Annual General Meeting in BioArctic AB (publ)
![BioArctic, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/86b2a76b-da7c-417b-a4f5-3ee79a630844.png)